Mdma & cannabis: A mini-review of cognitive, behavioral, and neurobiological effects of co-consumption

Current Drug Abuse Reviews

Volumn 4, Issue 2, 2011, Pages 81-86

  Schulz, Sybille ^a  

^a UNIVERSITY OF BREMEN   (Germany)

Author keywords

Cannabinoid agents; Cannabis; Co consumption; Cognition; Mdma; Memory; Neurobiology; Serotonin

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CANNABINOID 1 RECEPTOR; CANNABIS;

ANIMAL BEHAVIOR; BEHAVIORAL SCIENCE; BODY TEMPERATURE; COGNITIVE DEFECT; DECISION MAKING; DOPAMINERGIC SYSTEM; EXECUTIVE FUNCTION; HIPPOCAMPUS; HUMAN; HYPERACTIVITY; HYPERTHERMIA; IMPULSIVENESS; MEMORY DISORDER; MULTIPLE DRUG ABUSE; NEUROBIOLOGY; NEUROTOXICITY; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; REINFORCEMENT; REVIEW; SEROTONINERGIC SYSTEM; WORKING MEMORY;

EID: 79960606027     PISSN: 18744737     EISSN: 18744745     Source Type: Journal    
DOI: 10.2174/1874473711104020081     Document Type: Review

References (62)

1. [The EMCDDA annual report 2010: the state of the drugs problem in Europe. Euro Surveill 2010; 15(46).
2. Scholey AB, Parrott AC, Buchanan T, Heffernan TM, Ling J, Rodgers J. Increased intensity of Ecstasy and polydrug usage in the more experienced recreational Ecstasy/MDMA users: a WWW study. Addict Behav 2004; 29(4): 743-52.
3. Braida D, Iosue S, Pegorini S, Sala M. 3,4 Methylenedioxymethamphetamine-induced conditioned place preference (CPP) is mediated by endocannabinoid system. Pharmacol Res 2005; 51(2): 177-82.
4. Fox HC, Parrott AC, Turner JJ. Ecstasy use: cognitive deficits related to dosage rather than self-reported problematic use of the drug. J Psychopharmacol 2001; 15(4): 273-81.
5. Gouzoulis-Mayfrank E, Daumann J. The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview. J Psychopharmacol 2006; 20(2): 188-93.
6. Keyes KM, Martins SS, Hasin DS. Past 12-month and lifetime comorbidity and poly-drug use of ecstasy users among young adults in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Drug Alcohol Depend 2008; 97(1-2): 139-49.
7. Wu LT, Parrott AC, Ringwalt CL, Yang C, Blazer DG. The variety of ecstasy/MDMA users: results from the National Epidemiologic Survey on alcohol and related conditions. Am J Addict 2009; 18(6): 452-61.
8. Grov C, Kelly BC, Parsons JT. Polydrug use among club-going young adults recruited through time-space sampling. Subst Use Misuse 2009; 44(6): 848-64.
9. Smith GW, Farrell M, Bunting BP, Houston JE, Shevlin M. Patterns of polydrug use in Great Britain: findings from a national household population survey. Drug Alcohol Depend 2011; 113(2-3): 222-8.
10. Parrott AC, Gouzoulis-Meyfrank E, Rodgers J, Solowij N. Ecstasy/MDMA and cannabis: the complexities of their interactive neuropsychobiological effects. J Psychopharmacol 2004; 18(4): 572-5.
11. Degenhardt L, Hall W, Lynskey M. The relationship between cannabis use and other substance use in the general population. Drug Alcohol Depend 2001; 64(3): 319-327.
12. Winstock AR, Griffiths P, Stewart D. Drugs and the dance music scene: a survey of current drug use patterns among a sample of dance music enthusiasts in the UK. Drug Alcohol Depend 2001; 64(1): 9-17.
13. Morton J. Ecstasy: pharmacology and neurotoxicity. Curr Opin Pharmacol 2005; 5(1): 79-86.
14. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy). Pharmacol Rev 2003; 55(3): 463-508.
15. Boys A, Marsden J, Strang J. Understanding reasons for drug use amongst young people: a functional perspective. Health Educ Res 2001; 16(4): 457-69.
16. Cole JC, Sumnall HR. The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine (MDMA). Neurosci Biobehav Rev 2003; 27(3): 199-217.
17. Hall WD, Degenhardt LJ, Currow D. Allowing the medical use of cannabis. Med J Aust 2001; 175(1): 39-40.
18. Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 2004; 47(Suppl 1): 345-58.
19. Parrott AC, Milani RM, Gouzoulis-Mayfrank E, Daumann J. Cannabis and Ecstasy/MDMA (3,4-methylenedioxymethamphetamine): an analysis of their neuropsychobiological interactions in recreational users. J Neural Transm 2007; 114(8): 959-68.
20. Parrott AC. Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity. Psychopharmacology (Berl) 2004; 173(3-4): 234-41.
21. [World Drug Report 2010 of the United Nations Office on Drugs and Crime. 2010.
22. Verdejo-Garcia AJ, Lopez-Torrecillas F, Aguilar dA, Perez-Garcia M. Differential effects of MDMA, cocaine, and cannabis use severity on distinctive components of the executive functions in polysubstance users: a multiple regression analysis. Addict Behav 2005; 30(1): 89-101.
23. Morgan MJ, Impallomeni LC, Pirona A, Rogers RD. Elevated impulsivity and impaired decision-making in abstinent Ecstasy (MDMA) users compared to polydrug and drug-naive controls. Neuropsychopharmacology 2006; 31(7): 1562-73.
24. Brown J, McKone E, Ward J. Deficits of long-term memory in ecstasy users are related to cognitive complexity of the task. Psychopharmacology (Berl) 2010; 209(1): 51-67.
25. de Sola LS, Miguelez-Pan M, Pena-Casanova J, et al. Cognitive performance in recreational ecstasy polydrug users: a two-year follow-up study. J Psychopharmacol 2008; 22(5): 498-510.
26. Roberts GM, Garavan H. Evidence of increased activation underlying cognitive control in ecstasy and cannabis users. Neuroimage 2010; 52(2): 429-35.
27. Fernandez-Serrano MJ, Perez-Garcia M, Verdejo-Garcia A. What are the specific vs generalized effects of drugs of abuse on neuropsychological performance? Neurosci Biobehav Rev 2011; 35(3): 377-406.
28. Fisk JE, Montgomery C, Wareing M, Murphy PN. The effects of concurrent cannabis use among ecstasy users: neuroprotective or neurotoxic? Hum Psychopharmacol 2006; 21(6): 355-66.
29. Croft RJ, Mackay AJ, Mills AT, Gruzelier JG. The relative contributions of ecstasy and cannabis to cognitive impairment. Psychopharmacology (Berl) 2001; 153(3): 373-9.
30. Dafters RI, Hoshi R, Talbot AC. Contribution of cannabis and MDMA (ecstasy) to cognitive changes in long-term polydrug users. Psychopharmacology (Berl) 2004; 173(3-4): 405-10.
31. Clark L, Roiser JP, Robbins TW, Sahakian BJ. Disrupted 'reflection' impulsivity in cannabis users but not current or former ecstasy users. J Psychopharmacol 2009; 23(1): 14-22.
32. Lamers CT, Bechara A, Rizzo M, Ramaekers JG. Cognitive function and mood in MDMA/THC users, THC users and non-drug using controls. J Psychopharmacol 2006; 20(2): 302-11.
33. [Daumann J, Hensen G, Thimm B, Rezk M, Till B, Gouzoulis-Mayfrank E. Self-reported psychopathological symptoms in recreational ecstasy (MDMA) users are mainly associated with regular cannabis use: further evidence from a combined crosssectional/ longitudinal investigation. Psychopharmacology (Berl) 2004; 173(3-4): 398-404.
34. Schilt T, de Win MM, Jager G, et al. Specific effects of ecstasy and other illicit drugs on cognition in poly-substance users. Psychol Med 2008; 38(9): 1309-17.
35. Nulsen CE, Fox AM, Hammond GR. Differential effects of ecstasy on short-term and working memory: a meta-analysis. Neuropsychol Rev 2010; 20(1): 21-32.
36. Gouzoulis-Mayfrank E, Thimm B, Rezk M, Hensen G, Daumann J. Memory impairment suggests hippocampal dysfunction in abstinent ecstasy users. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27(5): 819-27.
37. Solowij N, Battisti R. The chronic effects of cannabis on memory in humans: a review. Curr Drug Abuse Rev 2008; 1(1): 81-98.
38. Murphy PN, Wareing M, Fisk JE, Montgomery C. Executive working memory deficits in abstinent ecstasy/MDMA users: a critical review. Neuropsychobiology 2009; 60(3-4): 159-175.
39. Scallet AC. Neurotoxicology of cannabis and THC: a review of chronic exposure studies in animals. Pharmacol Biochem Behav 1991; 40(3): 671-6.
40. Reneman L, Lavalaye J, Schmand B, et al. Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or ecstasy): preliminary findings. Arch Gen Psychiatry 2001; 58(10): 901-6.
41. Lundqvist T. Imaging cognitive deficits in drug abuse. Curr Top Behav Neurosci 2010; 3: 247-75.
42. Dumont G, Van Hasselt J, de Kam M, et al. Acute psychomotor, memory and subjective effects of MDMA and THC coadministration over time in healthy volunteers. J Psychopharmacol 2011; 25(4): 478-89.
43. Green AR, Gabrielsson J, Marsden CA, Fone KC. MDMA: On the translation from rodent to human dosing. Psychopharmacology (Berl) 2009; 204(2): 375-8.
44. Nagayasu K, Kitaichi M, Shirakawa H, Nakagawa T, Kaneko S. Sustained exposure to 3,4-methylenedioxymethamphetamine induces the augmentation of exocytotic serotonin release in rat organotypic raphe slice cultures. J Pharmacol Sci 2010; 113(2): 197-201.
45. Fiaschi AI, Cerretani D. Causes and effects of cellular oxidative stress as a result of MDMA abuse. Curr Pharm Biotechnol 2010; 11(5): 444-52.
46. De Petrocellis L, Di MV. Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels. J Neuroimmune Pharmacol 2010; 5(1): 103-21.
47. Sarne Y, Mechoulam R. Cannabinoids: between neuroprotection and neurotoxicity. Curr Drug Targets CNS Neurol Disord 2005; 4(6): 677-84.
48. Lopez-Moreno JA, Gonzalez-Cuevas G, Moreno G, Navarro M. The pharmacology of the endocannabinoid system: functional and structural interactions with other neurotransmitter systems and their repercussions in behavioral addiction. Addict Biol 2008; 13(2): 160-87.
49. Sano K, Mishima K, Koushi E, et al. Delta 9-tetrahydrocannabinolinduced catalepsy-like immobilization is mediated by decreased 5- HT neurotransmission in the nucleus accumbens due to the action of glutamate-containing neurons. Neuroscience 2008; 151(2): 320-8.
50. [Tourino C, Zimmer A, Valverde O. THC Prevents MDMA Neurotoxicity in Mice. PLoS One 2010; 5(2): e9143.
51. Manzanedo C, Rodriguez-Arias M, Daza-Losada M, Maldonado C, Aguilar MA, Minarro J. Effect of the CB1 cannabinoid agonist WIN 55212-2 on the acquisition and reinstatement of MDMAinduced conditioned place preference in mice. Behav Brain Funct 2010; 6(1): 19.
52. Sala M, Braida D. Endocannabinoids and 3,4-methylenedioxymethamphetamine (MDMA) interaction. Pharmacol Biochem Behav 2005; 81(2): 407-16.
53. Braida D, Sala M. Role of the endocannabinoid system in MDMA intracerebral self-administration in rats. Br J Pharmacol 2002; 136(8): 1089-92.
54. Stone DM, Hanson GR, Gibb JW. Differences in the central serotonergic effects of methylenedioxymethamphetamine (MDMA) in mice and rats. Neuropharmacology 1987; 26(11): 1657-61.
55. Kindlundh-Högberg AMS, Schiöth HB, Svenningsson P. Repeated intermittent MDMA binges reduce DAT density in mice and SERT density in rats in reward regions of the adolescent brain. Neurotoxicology 2007; 28(6): 1158-69.
56. Young JM, McGregor IS, Mallet PE. Co-administration of THC and MDMA ('ecstasy') synergistically disrupts memory in rats. Neuropsychopharmacology 2005; 30(8): 1475-82.
57. Nawata Y, Hiranita T, Yamamoto T. A cannabinoid CB(1) receptor antagonist ameliorates impairment of recognition memory on withdrawal from MDMA (Ecstasy). Neuropsychopharmacology 2010; 35(2): 515-20.
58. Morley KC, Li KM, Hunt GE, Mallet PE, McGregor IS. Cannabinoids prevent the acute hyperthermia and partially protect against the 5-HT depleting effects of MDMA (Ecstasy) in rats. Neuropharmacology 2004; 46(7): 954-65.
59. Rubino T, Parolaro D. Long lasting consequences of cannabis exposure in adolescence. Mol Cell Endocrinol 2008; 286(1-2 Suppl 1): S108-S113.
60. Meyer JS, Piper BJ, Vancollie VE. Development and characterization of a novel animal model of intermittent MDMA (Ecstasy) exposure during adolescence. Ann N Y Acad Sci 2008; 1139: 151-63.
61. Wegener N, Koch M. Behavioural disturbances and altered Fos protein expression in adult rats after chronic pubertal cannabinoid treatment. Brain Research 2009; 1253: 81-91.
62. Piper BJ, Ali SF, Daniels LG, Meyer JS. Repeated intermittent methylenedioxymethamphetamine exposure protects against the behavioral and neurotoxic, but not hyperthermic, effects of an MDMA binge in adult rats. Synapse 2010; 64(6): 421-31.